Aquestive Therapeutics, Inc. (AQST) — 8-K Filings

8-K Filings (39)

• Aquestive Therapeutics Files 8-K Disclosure — Mar 30, 2026 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on March 30, 2026, to disclose information under Regulation FD. The filing includes a press release and exhibits relat
• Aquestive Therapeutics Files 8-K — Nov 6, 2025 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on November 6, 2025, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The company, form
• Aquestive Therapeutics Files 8-K — Nov 5, 2025 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on November 5, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Fin
• Aquestive Therapeutics Files 8-K — Oct 8, 2025 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on October 8, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not detail speci
• Aquestive Therapeutics Files 8-K — Oct 1, 2025 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on October 1, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
• Aquestive Therapeutics Files 8-K — Sep 8, 2025 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on September 8, 2025, to report information under Regulation FD and to file financial statements and exhibits. The fil
• Aquestive Therapeutics Files 8-K — Sep 4, 2025 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on September 4, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, form
• Aquestive Therapeutics Files 8-K for Material Agreement — Aug 15, 2025 Risk: medium
  Aquestive Therapeutics, Inc. filed an 8-K on August 15, 2025, reporting an entry into a material definitive agreement on August 14, 2025. The filing also includ
• Aquestive Therapeutics Enters Material Definitive Agreement — Aug 14, 2025 Risk: medium
  Aquestive Therapeutics, Inc. announced on August 13, 2025, that it entered into a material definitive agreement. The company, formerly known as MonoSol Rx, Inc.
• Aquestive Therapeutics Files Routine 8-K — Jul 15, 2025 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on July 15, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specif
• Aquestive Therapeutics Files 8-K — Jun 16, 2025 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on June 16, 2025, reporting an event on June 13, 2025. The filing is primarily for Regulation FD Disclosure and includ
• Aquestive Therapeutics Files 8-K on Shareholder Vote Matters — Jun 11, 2025 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on June 11, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's c
• Aquestive Therapeutics Files 8-K — Jun 2, 2025 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on June 2, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
• Aquestive Therapeutics Files 8-K — Apr 1, 2025 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on April 1, 2025, reporting on financial statements and exhibits. The company, formerly known as MonoSol Rx, Inc., is
• Aquestive Therapeutics Files 8-K — Mar 10, 2025 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on March 10, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the
• Aquestive Therapeutics Files 8-K — Feb 12, 2025 Risk: low
  On February 12, 2025, Aquestive Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corp
• Aquestive Therapeutics Files 8-K on Financials — Jan 13, 2025 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulati
• Aquestive Therapeutics Files 8-K — Dec 19, 2024 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on December 19, 2024, reporting on other events and financial statements. The filing does not contain specific financi
• Aquestive Therapeutics Files 8-K — Dec 2, 2024 Risk: low
  On December 2, 2024, Aquestive Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, along with fina
• Aquestive Therapeutics Announces Board and Executive Changes — Nov 7, 2024 Risk: medium
  Aquestive Therapeutics, Inc. announced on November 1, 2024, changes in its board of directors and executive compensation arrangements. The filing details the de
• Aquestive Therapeutics Files 8-K — Nov 6, 2024 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on November 6, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details th
• Aquestive Therapeutics Files 8-K — Oct 25, 2024 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on October 25, 2024, reporting on other events and financial statements. The company, incorporated in Delaware with it
• Aquestive Therapeutics Files 8-K — Oct 24, 2024 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on October 24, 2024, reporting on other events and financial statements. The filing does not contain specific new mate
• Aquestive Therapeutics Files 8-K for Bylaws and Exhibits — Oct 16, 2024 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on October 16, 2024, to report amendments to its articles of incorporation or bylaws and to file financial statements
• Aquestive Therapeutics Files 8-K with Financials — Sep 27, 2024 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on September 27, 2024, reporting on various events. The filing includes financial statements and exhibits, and is cate
• Aquestive Therapeutics Files 8-K — Sep 9, 2024 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on September 9, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerl
• Aquestive Therapeutics Files 8-K — Aug 14, 2024 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on August 14, 2024, reporting other events and financial statements. The company, formerly known as MonoSol Rx, Inc.,
• Aquestive Therapeutics Files 8-K — Aug 6, 2024 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on August 6, 2024, to report on its results of operations and financial condition, as well as to provide a Regulation
• Aquestive Therapeutics Sells Subsidiary for $30M — Jul 25, 2024 Risk: medium
  Aquestive Therapeutics, Inc. announced on July 25, 2024, that it has entered into a definitive agreement to sell its subsidiary, Aquestive Pharma, LLC, to Amnea
• Aquestive Therapeutics Reports Shareholder Vote Matters — Jun 21, 2024 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on June 21, 2024, reporting on matters submitted to a vote of security holders on June 20, 2024. The filing does not d
• FDA Approves Aquestive's Libervant for Seizures — Jun 7, 2024 Risk: low
  Aquestive Therapeutics, Inc. announced on June 6, 2024, that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Liberva
• Aquestive Therapeutics Names New Directors, Adjusts Exec Pay — Jun 6, 2024 Risk: medium
  Aquestive Therapeutics, Inc. announced on June 3, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new
• Aquestive Therapeutics Sells MonoSol Rx for $10M — May 8, 2024 Risk: medium
  Aquestive Therapeutics, Inc. announced on May 7, 2024, that it has entered into a definitive agreement to sell its subsidiary, MonoSol Rx, Inc., to an undisclos
• Aquestive Therapeutics Files 8-K for Financials — May 7, 2024 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on May 7, 2024, to report on its results of operations and financial condition, as well as to provide Regulation FD di
• Aquestive Therapeutics Files 8-K — Apr 29, 2024 Risk: low
  Aquestive Therapeutics, Inc. filed an 8-K on April 29, 2024, reporting on events that occurred on April 26, 2024. The filing primarily concerns financial statem
• Aquestive Therapeutics Sells Subsidiary MonoSol Rx — Apr 22, 2024 Risk: medium
  Aquestive Therapeutics, Inc. announced on April 22, 2024, that it has entered into a definitive agreement to sell its subsidiary, MonoSol Rx, Inc., to an undisc
• Aquestive Therapeutics Reports Leadership Changes — Apr 1, 2024 Risk: medium
  Aquestive Therapeutics, Inc. filed an 8-K on April 1, 2024, reporting changes in its board of directors and executive officers, as well as updates to compensato
• Aquestive Therapeutics Enters Material Definitive Agreement — Mar 21, 2024 Risk: medium
  On March 19, 2024, Aquestive Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial stateme
• Aquestive Therapeutics Closes $100M Public Offering — Mar 15, 2024 Risk: medium
  On March 14, 2024, Aquestive Therapeutics, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully raised

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX